NUTRIBAND INC (NTRB) Stock News
NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD
NTRB Latest News, Press Relases and Analysis
Nutriband CEO Publishes Letter to Shareholders
2025 Letter to Shareholders...
Nutriband CEO Publishes Letter to Shareholders
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
Nutriband increases Patent protection with the addition of Macao...
Nutriband Issues Letter to Shareholders
CEO Publishes Letter to Shareholders looking over achievements in 2024 and outlook for 2025...
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
Serguei Melnik will present at the Noble Conference to discuss the companies latest advances with its AVERSA technology ...
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical...
Nutriband Signs Partnership Agreement with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical...
Nutriband Signs Partnership Agreement with Charlotte FC
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
Issued new Trademark...
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Partnership Agreement...
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical...
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
U.S. Patent Office issues Notice of Allowance for new patent covering Nutriband's AVERSA™ technology...
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia
Nutriband Issues Letter to Shareholders
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Chinese Patent for AVERSA extended to Macao...
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Nutriband Inc. Q3 report and highlights...
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
Nutriband Inc receives Hong Kong Patent Notice of Publication for its AVERSA patent application bringing the total number of countries covered to 46...
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch
